TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study was to compare the medication TP05 to the medication
Asacol™ for the treatment of ulcerative colitis (UC) and to assess the safety and
tolerability of TP05. This study investigated whether TP05 is as good as (non-inferior to)
Asacol™(1).
(1)The trademark Asacol™ is registered in over 55 countries as Asacol™ and as Octasa™,
Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively.
The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG
in various countries except for the following: Switzerland, USA, United Kingdom, Canada,
Italy, Belgium, the Netherlands and Luxembourg.